Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY

This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

开始日期2024-12-01

申办/合作机构

Hoosier Cancer Research Network

[+1]

100 项与 PARP1 x CYP17A1 x PARP2 相关的临床结果

登录后查看更多信息

100 项与 PARP1 x CYP17A1 x PARP2 相关的转化医学

登录后查看更多信息

0 项与 PARP1 x CYP17A1 x PARP2 相关的专利（医药）

登录后查看更多信息

项与 PARP1 x CYP17A1 x PARP2 相关的文献（医药）

2023-05-08·The oncologist

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.

Article

作者: Chi, Kim N ; De Porre, Peter ; Mason, Gary E ; Chiuri, Vincenzo Emanuele ; Maul, Raymond Scott ; Van Bruwaene, Siska ; Hafron, Jason ; Zhong, Xiaogang ; Daksh, Mahesh ; Tutrone, Ronald F ; Fleshner, Neil ; McNeel, Douglas G

Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.

项与 PARP1 x CYP17A1 x PARP2 相关的新闻（医药）

2024-10-21

·Pharma CMC

强生「尼拉帕利阿比特龙片」获批上市，治疗前列腺癌

刚刚，强生发布公告，旗下创新治疗药物泽倍珂（尼拉帕利阿比特龙片）正式获得国家药品监督管理局批准。作为目前国内首个且唯一获批的双效复方制剂，泽倍珂联合泼尼松或泼尼松龙用于治疗携带胚系和/或体系 BRCA 基因突变的转移性去势抵抗性前列腺癌成人患者（mCRPC）。泽倍珂®是每日一次的口服复方制剂，用于联合泼尼松或泼尼松龙一线治疗携带BRCA1/2突变的转移性去势抵抗性前列腺癌成人患者，临床证实其相较标准治疗可显著延长影像学无进展生存期。近年来，中国前列腺癌的发病率显著上升。据国家癌症中心最新发布的2022年度中国恶性肿瘤疾病负担报告显示，我国前列腺癌的发病率为每10万人中18.61例，已成为男性泌尿生殖系统中最常见的肿瘤。泽倍珂®是BRCA1/2突变mCRPC成人患者的一线靶向治疗方案。作为一种高选择性聚腺苷二磷酸核糖聚合酶(PARP)抑制剂，尼拉帕利和醋酸阿比特龙的组合联合泼尼松或泼尼松龙，能够靶向mCRPC患者的两种致癌驱动因素——雄激素受体轴和BRCA1/2突变。经临床验证，泽倍珂®联合泼尼松或泼尼松龙可显著延长BRCA1/2突变mCRPC患者的影像学无进展生存期（rPFS）。此外，与安慰剂相比，尼拉帕利还显示出总体生存 (OS)改善的趋势，可显著延长至症状进展时间（TSP）和至细胞毒性化疗起始时间（TCC），同时并维持了患者的生活质量。内容来源于网络，如有侵权，请联系删除。